Abstract
Systemically administered fluorescein (F) is rapidly transformed to the fluorescent metabolite fluorescein glucuronide (FG). Little is known about how diseases can influence the synthesis or disposition of FG. We studied F and FG in the plasma ultrafiltrate of 75 people who were normal or had diabetes, retinitis pigmentosa, or idiopathic rhegmatogenous retinal detachment. F and FG were determined by high-performance liquid chromatography. The concentration of FG was comparable to F 1 h after an intravenous injection of F, both in normal subjects and in patients with retinitis pigmentosa, which suggests that FG may not be an important contributor to the vitreous fluorescence at that time. At later times FG substantially exceeded F. The concentration of FG was significantly higher in diabetics than in the other groups 14 h after an oral dose of F. Accordingly, the possible effect of disease on plasma dye concentrations should be considered in studies measuring F by fluorescence hours after systemic F administration, since this could influence the intraocular fluorescence irrespective of any alteration in ocular function.
Similar content being viewed by others
References
Araie M, Sawa M, Nagataki S, Mishima S (1980) Aqueous humor dynamics in man as studied by oral fluorescein. Jpn J Ophthalmol 24:346–362
Blair NP, Zeimer RC, Rusin MM, Cunha-Vaz JG (1983) Outward transport of fluorescein from the vitreous in normal human subjects. Arch Ophthalmol 101:1117–1121
Blair NP, Evans MA, Lesar TS, Zeimer RC (1986) Fluorescein and fluorescein glucuronide pharmacokinetics after intravenous injection. Invest Ophthalmol Vis Sci 27:1107–1114
Chahal PS, Neal MJ, Kohner EM (1985) Metabolism of fluorescein after intravenous administration. Invest Ophthalmol Vis Sci 26:764–768
Chen SC, Nakamura H, Tamura Z (1980) Studies on the metabolites of fluorescein in rabbit and human urine. Chem Pharm Bull 28:1403–1407
Chen SC, Nakamura H, Tamura Z (1980) Determination of fluorescein and fluorescein monoglucuronide excreted in urine. Chem Pharm Bull (Tokyo) 28:2812–2816
Cunha-Vaz J, Faria de Abreu JR, Campos AJ, Figo GM (1975) Early breakdown of the blood-retinal barrier in diabetes. Br J Ophthalmol 59:649–656
Goldmann H (1950) Ueber Fluorescein in der menschlichen Vorderkammer: Das Kammerwasser-Minutenvolumen des Menschen. Ophthalmologica 119:65–95
Grotte D, Mattox V, Brubaker RF (1983) Fluorescein glucuronide: Can this metabolite interfere with fluorescein tracer studies? Trans Am Ophthalmol Soc 81:125–129
Grotte D, Mattox V, Brubaker R (1985) Fluorescent, physiological and pharmacological properties of fluorescein glucuronide. Exp Eye Res 40:23–33
Kitano S, Hori S, Nagataki S (1988) Transport of fluorescein in the rabbit eye after treatment with sodium iodate. Exp Eye Res 46:863–870
Lund-Andersen H, Larsen M, Dalgaard P, Olsen W (1987) Fluorescein and fluorescein glucuronide in the vitreous body of diabetic patients. Graefe's Arch Clin Exp Ophthalmol 225:173–176
McLaren JW, Brubaker RF (1986) Measurement of fluorescein and fluorescein monoglucuronide in the living human eye. Invest Ophthalmol Vis Sci 27:966–974
Mallick KS, Zeimer RC, Fishman GA, Blair NP, Anderson RJ (1984) Transport of fluorescein in the ocular posterior segment in retinitis pigmentosa. Arch Ophthalmol 102:691–696
Nagataki S (1975) Aqueous humor dynamics of human eyes as studied using fluorescein. Jpn J Ophthalmol 19:235–249
Neault TR, McLaren JW, Brubaker JH, Brubaker RF (1986) Spectral shift of fluorescein and carboxyfluorescein in the anterior chamber of the rabbit eye following systemic administration. Curr Eye Res 5:337–341
Palestine AG, Brubaker RF (1981) Pharmacokinetics of fluorescein in the vitreous. Invest Ophthalmol Vis Sci 21:542–549
Plehwe WE, Chahal PS, Fallon TJ, Cunningham JR, Neal MJ, Kohner EM (1987) Role of fluorescein glucuronide and its metabolism in vitreous fluorophotometry. Exp Eye Res 44:209–215
Sakai Y, Seto C, Araie M (1986) Study of fluorescein glucuronide. 1 Isolation from urine. Graefe's Arch Clin Exp Ophthalmol 224:110–112
Selan F, Blair NP, Evans MA (1985) High-performance liquid chromatographic analysis for fluorescein and fluorescein monoglucuronide in plasma. J Chromatogr 338:213–218
Seto C, Araie M, Takase M, Minoda K (1984) The effects of fluorescein monoglucuronide on the calculation of the transfer coefficient by diffusion (kdpa) after systemic administration of fluorescein. Nippon Ganka Gakkai Zasshi 88:1572–1580
Seto C, Araie M, Takase M (1986) Study of fluorescein glucuronide. II. A comparative ocular kinetic study of fluorescein and fluorescein glucuronide. Graefe's Arch Clin Exp Ophthalmol 224:113–117
Waltman SR, Oestrich C, Krupin T, Hanish S, Ratzan S, Santiago J, Kilo C (1978) Quantitative vitreous fluorophotometry. A sensitive technique for measuring early breakdown of the blood-retinal barrier in young diabetic patients. Diabetes 27:85–87
Zeimer RC, Blair NP, Cunha-Vaz JG (1983) Pharmacokinetic interpretation of vitreous fluorophotometry. Invest Ophthalmol Vis Sci 24:1374–1381
Author information
Authors and Affiliations
Additional information
Supported in part by Public Health Service Research Grant EY03106 and Ophthalmic Research Center Core Grant 1792 from the National Eye Institute, Bethesda, Maryland, and an unrestricted grant from Research to Prevent Blindness, New York, NY
Rights and permissions
About this article
Cite this article
Blair, N.P., Evans, M.A., Lesar, T.S. et al. Plasma fluorescein and fluorescein glucuronide in patients with selected eye diseases. Graefe's Arch Clin Exp Ophthalmol 227, 114–117 (1989). https://doi.org/10.1007/BF02169781
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02169781